Mary Wilson
Well-known member
Published: 28 April 2021
https://doi.org/10.1093/ofid/ofab217
Chiara Sepulcri, Chiara Dentone, Malgorzata Mikulska, Bianca Bruzzone, Alessia Lai, Daniela Fenoglio, Federica Bozzano, Annalisa Bergna, Alessia Parodi, Tiziana Altosole,
Emanuele Delfino, Giulia Bartalucci, Andrea Orsi, Antonio Di Biagio, Gianguglielmo Zehender, Filippo Ballerini, Stefano Bonora, Alessandro Sette, Raffaele De Palma, Guido Silvestri, Andrea De Maria, Matteo Bassetti
Abstract
Background
Immunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case of a prolonged persistence of viable SARS-CoV-2 associated with clinical relapses of COVID-19 in a patient with mantle-cell lymphoma who underwent treatment with R-BAC (rituximab, bendamustine, cytarabine) with consequent lymphopenia and hypogammaglobulinemia.
Methods
Nasopharyngeal swabs and blood samples were tested for SARS-CoV-2 by Real time-PCR (RT-PCR). On five positive nasopharyngeal swabs, we performed viral culture and next generation sequencing.We analysed the patients? adaptive and innate immunity to characterize T and NK cell subsets.
Results
SARS-CoV-2 RT-PCR on nasopharyngeal swabs samples remained positive for 268 days. All five performed viral cultures were positive and genomic analysis confirmed a persistent infection with the same strain. Viremia resulted positive in three out of four COVID-19 clinical relapses and cleared each time after remdesivir treatment. T and NK cells dynamic was different in aviremic and viremic samples and no SARS-CoV-2 specific antibodies were detected throughout the disease course.
Conclusions
In our patient, SARS-CoV-2 persisted with proven infectivity for over eight months. Viremia was associated with COVID-19 relapses and remdesivir treatment was effective in viremia clearance and symptoms remission, although it was unable to clear the virus from the upper respiratory airways.During the viremic phase, we observed a low frequency of terminal effector CD8+ T lymphocytes in peripheral blood that are probably recruited in inflammatory tissue for viral eradication. In addition we found a high level of NK cells repertoire perturbation with a relevant involvement during SARS- CoV-2 viremia.
PDF format only:
https://watermark.silverchair.com/o...GDMJ-eEkvpPqhYAYSo_lEJkg4dCh1Okqw1xJPB9i8uWlk
https://doi.org/10.1093/ofid/ofab217
Chiara Sepulcri, Chiara Dentone, Malgorzata Mikulska, Bianca Bruzzone, Alessia Lai, Daniela Fenoglio, Federica Bozzano, Annalisa Bergna, Alessia Parodi, Tiziana Altosole,
Emanuele Delfino, Giulia Bartalucci, Andrea Orsi, Antonio Di Biagio, Gianguglielmo Zehender, Filippo Ballerini, Stefano Bonora, Alessandro Sette, Raffaele De Palma, Guido Silvestri, Andrea De Maria, Matteo Bassetti
Abstract
Background
Immunocompromised patients show prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs. We report a case of a prolonged persistence of viable SARS-CoV-2 associated with clinical relapses of COVID-19 in a patient with mantle-cell lymphoma who underwent treatment with R-BAC (rituximab, bendamustine, cytarabine) with consequent lymphopenia and hypogammaglobulinemia.
Methods
Nasopharyngeal swabs and blood samples were tested for SARS-CoV-2 by Real time-PCR (RT-PCR). On five positive nasopharyngeal swabs, we performed viral culture and next generation sequencing.We analysed the patients? adaptive and innate immunity to characterize T and NK cell subsets.
Results
SARS-CoV-2 RT-PCR on nasopharyngeal swabs samples remained positive for 268 days. All five performed viral cultures were positive and genomic analysis confirmed a persistent infection with the same strain. Viremia resulted positive in three out of four COVID-19 clinical relapses and cleared each time after remdesivir treatment. T and NK cells dynamic was different in aviremic and viremic samples and no SARS-CoV-2 specific antibodies were detected throughout the disease course.
Conclusions
In our patient, SARS-CoV-2 persisted with proven infectivity for over eight months. Viremia was associated with COVID-19 relapses and remdesivir treatment was effective in viremia clearance and symptoms remission, although it was unable to clear the virus from the upper respiratory airways.During the viremic phase, we observed a low frequency of terminal effector CD8+ T lymphocytes in peripheral blood that are probably recruited in inflammatory tissue for viral eradication. In addition we found a high level of NK cells repertoire perturbation with a relevant involvement during SARS- CoV-2 viremia.
PDF format only:
https://watermark.silverchair.com/o...GDMJ-eEkvpPqhYAYSo_lEJkg4dCh1Okqw1xJPB9i8uWlk